Effects of dipyridamole on the short-term evolution of glomerulonephritis.
The aim of the present study is to evaluate the effect of dipyridamole (300 mg/day) versus placebo in a double-blind randomized trial on membranous glomerulonephritis (M-GMN), mesangial IgA glomerulonephritis (IgA-GMN), and segmentary and focal hyalinosis glomerulonephritis (SFH-GMN) during the first 3 months of treatment. In the case of M-GMN, proteinuria dropped by 60% of the basal value in patients treated with dipyridamole; in the case of IgA-GMN it dropped by 65-70%; and in the case of SFH-GMN it dropped by 40% of the basal value. Inhibition of proteinuria in M-GMN was correlated to platelet response, and above all, to the ADP-induced platelet aggregation in whole blood.
Camara
S
S
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
de la Cruz
J P
JP
Frutos
M A
MA
Sanchez
P
P
Lopez de Novales
E
E
Sanchez
E
E
Sanchez de la Cuesta
F
F
D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D013997:Time Factors
D004176:Dipyridamole